# CameL-Sq (NCT03668496)

> A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

No report yet. It can be ordered.

- Drugs tested: camrelizumab
- Indication: first-line stage IV squamous NSCLC

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03668496
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Conditions: Lung Cancer Squamous Cell; Lung Cancer Stage IV; PD-1 Antibody; Chemotherapy Effect
- Interventions: SHR-1210; The placebo
- Enrollment: 390
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on CameL-Sq so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 9 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=camel-sq-nct03668496

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03668496", "email": "<work email>"}; the inbox owner confirms by the emailed link.